Table 2 |
||||||
|
Characteristics of patients in the training set |
||||||
|
Sample ID |
Age (years) |
Sex |
Bacterial isolation |
Antibiotherapy before blood collection |
Underlying diseases |
Survival |
|
|
||||||
|
Other sepsis (n = 13) |
||||||
|
I001* |
52 |
Male |
Streptococcus non-group A or B |
Ceftriaxone |
- |
Non-survivor |
|
I002†‡ |
52 |
Female |
A. baumannii |
Ceftazidime, bactrim |
T2D, CRF, lung edema |
Survivor |
|
I004* ‡ |
45 |
Male |
Salmonella serotype B |
Cloxacillin, ceftriaxone |
T2D, arthritis |
Survivor |
|
I006* § |
37 |
Male |
C. albicans |
Ceftriaxone, sulperazone, bactrim |
HIV infection, tuberculosis |
Survivor |
|
I007* |
73 |
Female |
Corynebacterium spp. |
- |
NSAID-induced GI bleeding |
Non-survivor |
|
I008†¶ |
70 |
Female |
E. coli |
Bactrim, ceftazidime |
T2D |
Survivor |
|
I009* |
52 |
Female |
S. aureus |
Ceftazidime, cloxacillin |
T2D, knee abscess |
Survivor |
|
I010†‡¥ |
72 |
Female |
E. coli |
Ceftriaxone |
T2D, CRF |
Survivor |
|
I011* ¶ |
38 |
Female |
E. coli |
- |
HCV infection |
Survivor |
|
I012* § |
69 |
Female |
C. albicans |
Ceftazidime |
RF |
Survivor |
|
I013* |
74 |
Female |
Corynebacterium spp. |
Ceftazidime, clarithromycin |
Chronic heart failure, COPD |
Survivor |
|
I014* |
54 |
Female |
Salmonella spp. |
Ceftriaxone, ceftazidime, levofloxacin |
T2D, endometrial cancer, ITP |
Survivor |
|
I015* § |
41 |
Male |
C. albicans |
Ceftazidime |
HIV infection |
Survivor |
|
Septicemic melioidosis (n = 11) |
||||||
|
M001* |
68 |
Male |
B. pseudomallei |
Ceftazidime, bactrim |
Chronic heart failure, COPD |
Non-survivor |
|
M002* |
43 |
Female |
B. pseudomallei |
Ceftriaxone, ceftazidime |
T2D |
Survivor |
|
M003* |
55 |
Male |
B. pseudomallei |
Ceftazidime |
- |
Non-survivor |
|
M006* |
46 |
Male |
B. pseudomallei |
Ceftriaxone |
T2D, chirrosis |
Non-survivor |
|
M007* |
50 |
Male |
B. pseudomallei |
Ceftazidime, tazocin |
Lung cancer |
Survivor |
|
M008* |
70 |
Female |
B. pseudomallei |
Ceftazidime, bactrim |
T2D |
Non-survivor |
|
M009* |
48 |
Female |
B. pseudomallei |
Sulperazone |
T2D |
Survivor |
|
M010* |
48 |
Male |
B. pseudomallei |
Ceftriaxone, ceftazidime, doxycycline |
T2D |
Survivor |
|
M012* |
56 |
Male |
B. pseudomallei |
Sulperazone, bactrim, cetazidime |
T1D, ARF |
Survivor |
|
M014* |
65 |
Female |
B. pseudomallei |
Cloxacilin, ceftazidime |
T2D, chirrosis |
Non-survivor |
|
M015* |
41 |
Male |
B. pseudomallei |
Bactrim, ceftazidime |
- |
Survivor |
|
|
||||||
|
*Community-acquired septicemia; †hospital-acquired septicemia;‡mechanical ventilation;§taken immunosuppressive;¶urinary catheterized drugs; ¥blood transfused. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; GI, gastrointestinal tract; NSAID, non-steroidal anti-inflammatory drug; RF, renal failure; T2D, type 2 diabetes; TP, idiopathic thrombocytopenic purpura. |
||||||
|
Pankla et al. Genome Biology 2009 10:R127 doi:10.1186/gb-2009-10-11-r127 |
||||||
